Amphetamine-group substances and HIV

Area of Science:

• Public Health
• Addiction Medicine
• Behavioral Science

Background:

• Amphetamine-group substances are globally prevalent, exceeding cocaine and opioid use.
• Non-injection amphetamine use is linked to increased HIV risk, especially in men who have sex with men.
• Underlying factors connecting amphetamine use and HIV risk remain poorly understood.

Purpose of the Study:

• To review published reports on amphetamine-group substances.
• To conduct a meta-analysis of randomized controlled trials for behavioral interventions targeting amphetamine use.
• To assess the effectiveness of behavioral interventions in reducing amphetamine use and associated risks.

Main Methods:

• Systematic review of published literature.
• Meta-analysis of 13 randomized controlled trials involving 1997 participants.
• Evaluation of behavioral interventions for amphetamine-group substance use.

Main Results:

• High-intensity behavioral interventions showed moderate effectiveness in reducing amphetamine-group substance use (effect size 0.28).
• No conclusive evidence demonstrated that behavioral interventions, as a group, are more effective than passive or minimal treatments.
• The association between amphetamine use and HIV risk is noted, though not universally consistent across all studies.

Conclusions:

• While high-intensity interventions show some promise, further research is needed.
• The search for scalable, sustainable interventions, including pharmacotherapies, for amphetamine-group substance use should be prioritized.
• More research is required to understand the complex factors driving amphetamine use and HIV risk.